Statera Biopharma reports $101M loss for 2021 fiscal year

FORT COLLINS — Drug manufacturing company Statera Biopharma Inc. (Nasdaq: STAB) posted a $101.8 million loss for the 2021 fiscal year, the company reported Friday. 

This report was for the fiscal year that ended Dec. 31, 2021, and was filed late. The $101.8 million loss was up from the $12.09 million the company lost in the 2020 fiscal year.

The majority of the increase comes from a $67.7 million impairment loss stemming from Statera’s previous merger with Cleveland BioLabs and its acquisition of ImQuest.

Research and development expenses were also up 124.3%, to $11.8 million from $5.26 million.

Statera does not generate revenue and…